Sign In
Buy MRK
$120.78
+1.69 (+1.41%)
At Close: Jun 11, 2026
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
10:31am, Friday, 12'th Jun 2026
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing
06:46pm, Thursday, 11'th Jun 2026
In the closing of the recent trading day, Merck (MRK) stood at $120.76, denoting a +1.4% move from the preceding trading day.
Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
02:26pm, Thursday, 11'th Jun 2026
Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
10:00am, Thursday, 11'th Jun 2026
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?
09:45am, Thursday, 11'th Jun 2026
One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow. See how their fundamentals stack up.
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
07:14am, Thursday, 11'th Jun 2026
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect
Merck Animal Health to Acquire TARGAN
06:45am, Thursday, 11'th Jun 2026
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced t
Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case
09:42am, Wednesday, 10'th Jun 2026
MRK has reclaimed its 50-day SMA while holding above its 200-day trendline, backed by Keytruda growth, pipeline advances and recent deals.
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
04:36pm, Tuesday, 09'th Jun 2026
Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir, while ending a lung cancer study.
Merck & Co., Inc. (MRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
02:22pm, Tuesday, 09'th Jun 2026
Merck & Co., Inc. (MRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial
01:44pm, Tuesday, 09'th Jun 2026
On Monday, Gilead Sciences Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) on Monday discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 trial evaluating Trodelvy plus Keytruda in previously untreated me
Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying
09:20am, Tuesday, 09'th Jun 2026
More employers and health plans are balking at paying for costly GLP-1 drugs like Ozempic, Zepbound and Wegovy for weight loss and the treatment of obesity, according to a new report.
FOSTER CITY, Calif., & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the primary
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
04:30pm, Monday, 08'th Jun 2026
RAHWAY, N.J. & FOSTER CITY, Calif.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (Nasdaq: GILD) today announced the
Rejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health
08:00am, Monday, 08'th Jun 2026
SAN DIEGO--(BUSINESS WIRE)-- #animalhealth--Rejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health.
